Rose Gelineau-Morel

Apr 8, 2024 | medrxiv.org | Rose Gelineau-Morel |Nomazulu Dlamini |Joel Bruss |Alexander Cohen

The authors have declared no competing interest. This work was supported by NIH NICHD T32HD069038 (RGM), The Auxilium Foundation (ND), NIMH K23MH120510 and the Simons Foundation Autism Research Initiative (AC), NIH NICHD P50 HD103525 (CDS), and NIH NINDS 3R01NS114405 (AB). I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Feb 3, 2024 | medrxiv.org | Darcy Fehlings |Rose Gelineau-Morel |Michael C Kruer |Emma Lott

The authors have declared no competing interest. NINDS 1K08NS117850-01A1 (BRA), NICHD T32HD069038 (RGM)I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of Washington University School of Medicine in St. Louis waived ethical approval for this work (IRB ID# 201910233, 11/04/2019).